Man Group plc Makes New $5.79 Million Investment in Baxter International Inc. $BAX

Key Points

• Man Group acquired 271,465 Baxter International shares during the second quarter, valued at approximately $5.79 million. Institutional investors now own 90.19% of the company, with BlackRock and Pzena also establishing sizable new positions.
• Baxter reported quarterly EPS of $0.56, beating the $0.37 analyst consensus, while revenue rose 5.3% year over year to $2.96 billion. The company issued fiscal 2026 EPS guidance of $1.95–$2.15.
• Analysts maintain a consensus “Hold” rating, with an average price target of $22.45, below the stock’s reported $26.13 opening price. Baxter also declared a quarterly dividend of $0.01 per share, implying a 0.2% annualized yield.

Man Group plc acquired a new stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 271,465 shares of the medical instruments supplier's stock, valued at approximately $5,788,000. Man Group plc owned 0.05% of Baxter International at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Baxter International in the 2nd quarter worth $1,744,874,000. Pzena Investment Management LLC purchased a new position in shares of Baxter International during the second quarter valued at about $1,392,098,000. Geode Capital Management LLC grew its position in shares of Baxter International by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier's stock valued at $257,174,000 after purchasing an additional 972,891 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Baxter International by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier's stock worth $231,304,000 after purchasing an additional 97,687 shares during the last quarter. Finally, Equity Investment Corp purchased a new stake in shares of Baxter International in the second quarter worth about $146,815,000. Hedge funds and other institutional investors own 90.19% of the company's stock.

Baxter International Price Performance

Baxter International stock opened at $26.13 on Friday. The stock has a market cap of $13.51 billion, a price-to-earnings ratio of -12.62, a price-to-earnings-growth ratio of 3.96 and a beta of 0.60. The firm has a 50-day moving average of $24.24 and a two-hundred day moving average of $20.55. Baxter International Inc. has a 1 year low of $15.73 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32.

Baxter International (NYSE:BAX - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter in the prior year, the company earned $0.59 EPS. The business's revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, research analysts forecast that Baxter International Inc. will post 2.04 earnings per share for the current year.

Baxter International Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International's dividend payout ratio (DPR) is currently -1.93%.

Wall Street Analyst Weigh In

BAX has been the topic of a number of recent research reports. Citigroup raised shares of Baxter International from a "sell" rating to a "neutral" rating and upped their price target for the company from $17.00 to $28.00 in a research note on Friday, July 31st. Wells Fargo & Company boosted their target price on shares of Baxter International from $19.00 to $23.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Weiss Ratings upgraded shares of Baxter International from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, July 31st. Zacks Research raised shares of Baxter International from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Finally, TD Cowen lifted their price target on Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a research report on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Baxter International currently has a consensus rating of "Hold" and an average price target of $22.45.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source